REFERENCES

Rhoden A, Friedrich FW, Brandt T, Raabe J, Schweizer M, Meisterknecht J, Wittig I, Ulmer BM, Klampe B, Uebeler J, Piasecki A, Lorenz K, Eschenhagen T, Hansen A, Cuello F (2021) Sulforaphane exposure impairs contractility and mitochondrial function in three-dimensional engineered heart tissue. Redox Biol in press

Querdel E, Reinsch M, Castro L, Köse D, Bähr A, Reich S, Geertz B, Ulmer B, Schulze M, Lemoine MD, Krause T, Lemme M, Sani J, Shibamiya A, Stüdemann T, Köhne M, von Bibra CV, Hornaschewitz N, Pecha S, Nejahsie Y, Mannhardt I, Christ T, Reichenspurner H, Hansen A, Klymiuk N, Krane M, Kupatt C, Eschenhagen T, Weinberger F. Human Engineered Heart Tissue Patches Remuscularize the Injured Heart in a Dose-Dependent Manner. Circulation. 2021 Mar 2. doi: 10.1161/CIRCULATIONAHA.120.047904. Epub ahead of print. PMID: 33648345.

Madsen A, Krause J, Höppner G, Hirt MN, Tan WLW, Lim I, Hansen A, Nikolaev VO, Foo RSY, Eschenhagen T, Stenzig J. Hypertrophic signaling compensates for contractile and metabolic consequences of DNA methyltransferase 3A loss in human cardiomyocytes. J Mol Cell Cardiol. 2021 Feb 12;154:115-123. doi: 10.1016/j.yjmcc.2021.02.002. Epub ahead of print. PMID: 33582159.

de Korte T, Katili PA, Mohd Yusof NAN, van Meer BJ, Saleem U, Burton FL, Smith GL, Clements P, Mummery CL, Eschenhagen T, Hansen A, Denning C. Unlocking Personalized Biomedicine and Drug Discovery with Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Fit for Purpose or Forever Elusive? Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:529-551. doi: 10.1146/annurev-pharmtox-010919-023309. Epub 2019 Sep 10. PMID: 31506008.

Ulmer BM, Eschenhagen T. Human pluripotent stem cell-derived cardiomyocytes for studying energy metabolism. Biochim Biophys Acta Mol Cell Res. 2020 Mar;1867(3):118471. doi: 10.1016/j.bbamcr.2019.04.001. Epub 2019 Apr 4. PMID: 30954570; PMCID: PMC7042711.

Lemoine MD, Lemme M, Ulmer BM, Braren I, Krasemann S, Hansen A, Kirchhof P, Meyer C, Eschenhagen T, Christ T. Intermittent Optogenetic Tachypacing of Atrial Engineered Heart Tissue Induces Only Limited Electrical Remodelling. J Cardiovasc Pharmacol. 2020 Dec 13;77(3):291-299. doi: 10.1097/FJC.0000000000000951. PMID: 33278190.

Shibamiya A, Schulze E, Krauß D, Augustin C, Reinsch M, Schulze ML, Steuck S, Mearini G, Mannhardt I, Schulze T, Klampe B, Werner T, Saleem U, Knaust A, Laufer SD, Neuber C, Lemme M, Behrens CS, Loos M, Weinberger F, Fuchs S, Eschenhagen T, Hansen A, Ulmer BM (2020) Cell Banking of hiPSCs: A Practical Guide to Cryopreservation and Quality Control in Basic Research. Curr Protoc Stem Cell Biol 55: . https://doi.org/10.1002/cpsc.127

Mannhardt I, Saleem U, Mosqueira D, Loos MF, Ulmer BM, Lemoine MD, Larsson C, Améen C, de Korte T, Vlaming MLH, Harris K, Clements P, Denning C, Hansen A, Eschenhagen T (2020) Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format. Stem Cell Reports 15:983–998 . https://doi.org/10.1016/j.stemcr.2020.09.002

Funcke S, Werner TR, Hein M, Ulmer BM, Hansen A, Eschenhagen T, Hirt MN. Effects of the Delta Opioid Receptor Agonist DADLE in a Novel Hypoxia-Reoxygenation Model on Human and Rat-Engineered Heart Tissue: A Pilot Study. Biomolecules. 2020 Sep 11;10(9):1309. doi: 10.3390/biom10091309. PMID: 32932811; PMCID: PMC7565486.

Feyen DAM, McKeithan WL, Bruyneel AAN, Spiering S, Hörmann L, Ulmer B, Zhang H, Briganti F, Schweizer M, Hegyi B, Liao Z, Pölönen RP, Ginsburg KS, Lam CK, Serrano R, Wahlquist C, Kreymerman A, Vu M, Amatya PL, Behrens CS, Ranjbarvaziri S, Maas RGC, Greenhaw M, Bernstein D, Wu JC, Bers DM, Eschenhagen T, Metallo CM, Mercola M. Metabolic Maturation Media Improve Physiological Function of Human iPSC-Derived Cardiomyocytes. Cell Rep. 2020 Jul 21;32(3):107925. doi: 10.1016/j.celrep.2020.107925. PMID: 32697997; PMCID: PMC7437654.

Madsen A, Höppner G, Krause J, Hirt MN, Laufer SD, Schweizer M, Tan WLW, Mosqueira D, Anene-Nzelu CG, Lim I, Foo RSY, Eschenhagen T, Stenzig J. An Important Role for DNMT3A-Mediated DNA Methylation in Cardiomyocyte Metabolism and Contractility. Circulation. 2020 Oct 20;142(16):1562-1578. doi: 10.1161/CIRCULATIONAHA.119.044444. Epub 2020 Sep 4. PMID: 32885664; PMCID: PMC7566310.

Becker B, Rodriguez ML, Werner TR, Stenzig J, Eschenhagen T, Hirt MN. Magnetic Adjustment of Afterload in Engineered Heart Tissues. J Vis Exp. 2020 May 5;(159). doi: 10.3791/60811. PMID: 32449726.

Saleem U, van Meer BJ, Katili PA, Mohd Yusof NAN, Mannhardt I, Garcia AK, Tertoolen L, de Korte T, Vlaming MLH, McGlynn K, Nebel J, Bahinski A, Harris K, Rossman E, Xu X, Burton FL, Smith GL, Clements P, Mummery CL, Eschenhagen T, Hansen A, Denning C (2020c) Blinded, Multicenter Evaluation of Drug-induced Changes in Contractility Using Human-induced Pluripotent Stem Cell-derived Cardiomyocytes. Toxicol Sci 176:103–123 . https://doi.org/10.1093/toxsci/kfaa058

Bhagwan JR, Mosqueira D, Chairez-Cantu K, Mannhardt I, Bodbin SE, Bakar M, Smith JGW, Denning C (2020) Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics. JMCC 145:43-53. https://doi.org/10.1016/j.yjmcc.2020.06.003

Saleem U, Mannhardt I, Braren I, Denning C, Eschenhagen T, Hansen A (2020b) Force and Calcium Transients Analysis in Human Engineered Heart Tissues Reveals Positive Force-Frequency Relation at Physiological Frequency. Stem Cell Reports 14:312–324. https://doi.org/10.1016/j.stemcr.2019.12.011

Prondzynski M, Lemoine MD, Zech AT, Horváth A, Di Mauro V, Koivumäki JT, Kresin N, Busch J, Krause T, Krämer E, Schlossarek S, Spohn M, Friedrich FW, Münch J, Laufer SD, Redwood C, Volk AE, Hansen A, Mearini G, Catalucci D, Meyer C, Christ T, Patten M, Eschenhagen T, Carrier L. Disease modeling of a mutation in α-actinin 2 guides clinical therapy in hypertrophic cardiomyopathy. EMBO Mol Med. 2019 Dec;11(12):e11115. doi: 10.15252/emmm.201911115. Epub 2019 Nov 3. PMID: 31680489; PMCID: PMC6895603.

Rodriguez ML, Werner TR, Becker B, Eschenhagen T, Hirt MN. A magnetics-based approach for fine-tuning afterload in engineered heart tissues. ACS Biomater Sci Eng. 2019 Jul 8;5(7):3663-3675. doi: 10.1021/acsbiomaterials.8b01568. Epub 2019 Jun 11. PMID: 31637285; PMCID: PMC6803165.

Horváth A, Christ T, Koivumäki JT, Prondzynski M, Zech ATL, Spohn M, Saleem U, Mannhardt I, Ulmer B, Girdauskas E, Meyer C, Hansen A, Eschenhagen T, Lemoine MD (2020) Case Report on: Very Early Afterdepolarizations in HiPSC-Cardiomyocytes-An Artifact by Big Conductance Calcium Activated Potassium Current (Ibk,Ca). Cells 9: 253. https://doi.org/10.3390/cells9010253

Saleem U, Ismaili D, Mannhardt I, Pinnschmidt H, Schulze T, Christ T, Eschenhagen T, Hansen A (2020a) Regulation of ICa,L and force by PDEs in human-induced pluripotent stem cell-derived cardiomyocytes. Br J Pharmacol 177:3036–3045 . https://doi.org/10.1111/bph.15032

Lemme M, Braren I, Prondzynski M, Aksehirlioglu B, Ulmer BM, Schulze ML, Ismaili D, Meyer C, Hansen A, Christ T, Lemoine MD, Eschenhagen T. Chronic intermittent tachypacing by an optogenetic approach induces arrhythmia vulnerability in human engineered heart tissue. Cardiovasc Res. 2020 Jul 1;116(8):1487-1499. doi: 10.1093/cvr/cvz245. PMID: 31598634; PMCID: PMC7314638.

Werner TR, Kunze AC, Stenzig J, Eschenhagen T, Hirt MN. Blockade of miR-140-3p prevents functional deterioration in afterload-enhanced engineered heart tissue. Sci Rep. 2019 Aug 7;9(1):11494. doi: 10.1038/s41598-019-46818-0. PMID: 31391475; PMCID: PMC6686025.

Dutsch A, Wijnker PJM, Schlossarek S, Friedrich FW, Krämer E, Braren I, Hirt MN, Brenière-Letuffe D, Rhoden A, Mannhardt I, Eschenhagen T, Carrier L, Mearini G (2019) Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue. Sci Rep 9:18152 . https://doi.org/10.1038/s41598-019-54665-2

Pecha S, Yorgan K, Röhl M, Geertz B, Hansen A, Weinberger F, Sehner S, Ehmke H, Reichenspurner H, Eschenhagen T, Schwoerer AP. Human iPS cell-derived engineered heart tissue does not affect ventricular arrhythmias in a guinea pig cryo-injury model. Sci Rep. 2019 Jul 8;9(1):9831. doi: 10.1038/s41598-019-46409-z. PMID: 31285568; PMCID: PMC6614415.

Mannhardt I, Warncke C, Trieu HK, Müller J, Eschenhagen T (2019) Piezo-bending actuators for isometric or auxotonic contraction analysis of engineered heart tissue. J Tissue Eng Regen Med 13:3–11. doi: 10.1002/term.2755

Schulze ML, Lemoine MD, Fischer AW, Scherschel K, David R, Riecken K, Hansen A, Eschenhagen T, Ulmer BM. Dissecting hiPSC-CM pacemaker function in a cardiac organoid model. Biomaterials. 2019 Jun;206:133-145. doi: 10.1016/j.biomaterials.2019.03.023. Epub 2019 Mar 21. PMID: 30933775.

Castro L, Geertz B, Reinsch M, Aksehirlioglu B, Hansen A, Eschenhagen T, Reichenspurner H, Weinberger F, Pecha S. Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model. J Vis Exp. 2019 Mar 18;(145). doi: 10.3791/58810. PMID: 30933073.

Maffioletti SM, Sarcar S, Henderson ABH, Mannhardt I, Pinton L, Moyle LA, Steele-Stallard H, Cappellari O, Wells KE, Ferrari G, Mitchell JS, Tyzack GE, Kotiadis VN, Khedr M, Ragazzi M, Wang W, Duchen MR, Patani R, Zammit PS, Wells DJ, Eschenhagen T, Tedesco FS (2018) Three-Dimensional Human iPSC-Derived Artificial Skeletal Muscles Model Muscular Dystrophies and Enable Multilineage Tissue Engineering. Cell Rep 23:899–908. doi: 10.1016/j.celrep.2018.03.091

Mosqueira D, Mannhardt I, Bhagwan JR, Lis-Slimak K, Katili P, Scott E, Hassan M, Prondzynski M, Harmer SC, Tinker A, Smith JGW, Carrier L, Williams PM, Gaffney D, Eschenhagen T, Hansen A, Denning C (2018) CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy. Eur Heart J 39:3879–3892. doi: 10.1093/eurheartj/ehy249

Smith JGW, Owen T, Bhagwan JR, Mosqueira D, Scott E, Mannhardt I, Patel A, Barriales-Villa R, Monserrat L, Hansen A, Eschenhagen T, Harding SE, Marston S, Denning C (2018) Isogenic Pairs of hiPSC-CMs with Hypertrophic Cardiomyopathy/LVNC-Associated ACTC1 E99K Mutation Unveil Differential Functional Deficits. Stem cell reports 11:1226–1243. doi: 10.1016/j.stemcr.2018.10.006

Prüller J, Mannhardt I, Eschenhagen T, Zammit PS, Figeac N (2018) Satellite cells delivered in their niche efficiently generate functional myotubes in three-dimensional cell culture. PLoS One 13:e0202574. doi: 10.1371/journal.pone.0202574

Ulmer BM, Stoehr A, Schulze ML, Patel S, Gucek M, Mannhardt I, Funcke S, Murphy E, Eschenhagen T, Hansen A (2018) Contractile Work Contributes to Maturation of Energy Metabolism in hiPSC-Derived Cardiomyocytes. Stem cell reports 10:834–847. doi: 10.1016/j.stemcr.2018.01.039

Lemme M, Ulmer BM, Lemoine MD, Zech ATL, Flenner F, Ravens U, Reichenspurner H, Rol-Garcia M, Smith G, Hansen A, Christ T, Eschenhagen T. Atrial-like Engineered Heart Tissue: An In Vitro Model of the Human Atrium. Stem Cell Reports. 2018 Dec 11;11(6):1378-1390. doi: 10.1016/j.stemcr.2018.10.008. Epub 2018 Nov 8. PMID: 30416051; PMCID: PMC6294072.

Krause J, Löser A, Lemoine MD, Christ T, Scherschel K, Meyer C, Blankenberg S, Zeller T, Eschenhagen T, Stenzig J. Rat atrial engineered heart tissue: a new in vitro model to study atrial biology. Basic Res Cardiol. 2018 Sep 3;113(5):41. doi: 10.1007/s00395-018-0701-2. PMID: 30178427.

A. Horváth, M.D. Lemoine, A. Löser, I. Mannhardt, F. Flenner, A.U. Uzun, C. Neuber, K. Breckwoldt, A. Hansen, E. Girdauskas, H. Reichenspurner, S. Willems, N. Jost, E. Wettwer, T. Eschenhagen, T. Christ, Low Resting Membrane Potential and Low Inward Rectifier Potassium Currents Are Not Inherent Features of hiPSC-Derived Cardiomyocytes., Stem Cell Reports. (2018). doi:10.1016/j.stemcr.2018.01.012.

L. Sala, B.J. van Meer, L.G.J. Tertoolen, J. Bakkers, M. Bellin, R.P. Davis, C. Denning, M.A.E. Dieben, T. Eschenhagen, E. Giacomelli, C. Grandela, A. Hansen, E.R. Holman, M.R.M. Jongbloed, S.M. Kamel, C.D. Koopman, Q. Lachaud, I. Mannhardt, M.P.H. Mol, D. Mosqueira, V. V Orlova, R. Passier, M.C. Ribeiro, U. Saleem, G.L. Smith, F.L. Burton, C.L. Mummery, MUSCLEMOTION: A Versatile Open Software Tool to Quantify Cardiomyocyte and Cardiac Muscle Contraction In Vitro and In Vivo., Circ. Res. 122 (2018) e5–e16. doi:10.1161/CIRCRESAHA.117.312067.

M.D. Lemoine, I. Mannhardt, K. Breckwoldt, M. Prondzynski, H. Reichenspurner, S. Willems, A. Hansen, T. Eschenha-, Human iPSC-derived cardiomyocytes cultured in 3D engi- neered heart tissue show physiological upstroke velocity and sodium current density, (2017) 1–11. doi:10.1038/s41598-017-05600-w.

I. Mannhardt, A. Eder, B. Dumotier, M. Prondzynski, E. Krämer, M. Traebert, K.-D. Söhren, F. Flenner, K. Stathopoulou, M.D. Lemoine, L. Carrier, T. Christ, T. Eschenhagen, A. Hansen, Blinded Contractility Analysis in hiPSC-Cardiomyocytes in Engineered Heart Tissue Format: Comparison With Human Atrial Trabeculae., Toxicol. Sci. 158 (2017) 164–175. doi:10.1093/toxsci/kfx081.

K. Breckwoldt, D. Letuffe-Brenière, I. Mannhardt, T. Schulze, B. Ulmer, T. Werner, A. Benzin, B. Klampe, M.C. Reinsch, S. Laufer, A. Shibamiya, M. Prondzynski, G. Mearini, D. Schade, S. Fuchs, C. Neuber, E. Krämer, U. Saleem, M.L. Schulze, M.L. Rodriguez, T. Eschenhagen, A. Hansen, Differentiation of cardiomyocytes and generation of human engineered heart tissue, Nat. Protoc. 12 (2017) 1177–1197. doi:10.1038/nprot.2017.033.

F. Weinberger, I. Mannhardt, T. Eschenhagen, Engineering Cardiac Muscle Tissue, Circ. Res. 120 (2017) 1487–1500. doi:10.1161/CIRCRESAHA.117.310738.

I. Mannhardt, U. Saleem, A. Benzin, T. Schulze, B. Klampe, T. Eschenhagen, A. Hansen, Automated Contraction Analysis of Human Engineered Heart Tissue for Cardiac Drug Safety Screening, J. Vis. Exp. (2017) e55461–e55461. doi:10.3791/55461.

T. Ziegler, R. Hinkel, A. Stöhr, T. Eschenhagen, K.-L. Laugwitz, F. le Noble, R. David, A. Hansen, C. Kupatt, Thymosin β 4 Improves Differentiation and Vascularization of EHTs, Stem Cells Int. 2017 (2017) 1–10. doi:10.1155/2017/6848271.

D. Biermann, A. Eder, F. Arndt, H. Seoudy, H. Reichenspurner, T. Mir, A. Riso, R. Kozlik-Feldmann, K. Peldschus, M.G. Kaul, T. Schuler, S. Krasemann, A. Hansen, T. Eschenhagen, J.S. Sachweh, Towards a Tissue-Engineered Contractile Fontan-Conduit: The Fate of Cardiac Myocytes in the Subpulmonary Circulation, PLoS One. 11 (2016) e0166963. doi:10.1371/journal.pone.0166963.

F. Weinberger, K. Breckwoldt, S. Pecha, A. Kelly, B. Geertz, J. Starbatty, T. Yorgan, K.K.-H. Cheng, K. Lessmann, T. Stolen, M. Scherrer-Crosbie, G. Smith, H. Reichenspurner, A. Hansen, T. Eschenhagen, Cardiac repair in guinea pigs with human engineered heart tissue from induced pluripotent stem cells, Sci. Transl. Med. 8 (2016) 363ra148 LP-363ra148. doi:10.1126/scitranslmed.aaf8781.

A.U. Uzun, I. Mannhardt, K. Breckwoldt, A. Horváth, S.S. Johannsen, A. Hansen, T. Eschenhagen, T. Christ, Ca(2+)-Currents in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Effects of Two Different Culture Conditions., Front. Pharmacol. 7 (2016) 300. doi:10.3389/fphar.2016.00300.

F. Jacob, A.Y. Yonis, F. Cuello, P. Luther, T. Schulze, A. Eder, T. Streichert, I. Mannhardt, M.N. Hirt, S. Schaaf, J. Stenzig, T. Force, T. Eschenhagen, A. Hansen, Analysis of Tyrosine Kinase Inhibitor-Mediated Decline in Contractile Force in Rat Engineered Heart Tissue, PLoS One. 11 (2016) e0145937. doi:10.1371/journal.pone.0145937.

I. Mannhardt, K. Breckwoldt, D. Letuffe-Brenière, S. Schaaf, H. Schulz, C. Neuber, A. Benzin, T. Werner, A. Eder, T. Schulze, B. Klampe, T. Christ, M.N. Hirt, N. Huebner, A. Moretti, T. Eschenhagen, A. Hansen, Human Engineered Heart Tissue: Analysis of Contractile Force, Stem Cell Reports. 7 (2016) 29–42. doi:10.1016/j.stemcr.2016.04.011.

A. Eder, I. Vollert, A. Hansen, T. Eschenhagen, Human engineered heart tissue as a model system for drug testing, Adv. Drug Deliv. Rev. (2015). doi:10.1016/j.addr.2015.05.010.

A. Stoehr, M.N. Hirt, A. Hansen, M. Seiffert, L. Conradi, J. Uebeler, F.P. Limbourg, T. Eschenhagen, Spontaneous Formation of Extensive Vessel-Like Structures in Murine Engineered Heart Tissue., Tissue Eng. Part A. 22 (2016) 326–35. doi:10.1089/ten.TEA.2015.0242.

J. Fiedler, K. Breckwoldt, C.W. Remmele, D. Hartmann, M. Dittrich, A. Pfanne, A. Just, K. Xiao, M. Kunz, T. Müller, A. Hansen, R. Geffers, T. Dandekar, T. Eschenhagen, T. Thum, Development of Long Noncoding RNA-Based Strategies to Modulate Tissue Vascularization., J. Am. Coll. Cardiol. 66 (2015) 2005–15. doi:10.1016/j.jacc.2015.07.081.

A. Görbe, A. Eder, Z. V Varga, J. Pálóczi, A. Hansen, P. Ferdinandy, T. Eschenhagen, Protection by the NO-Donor SNAP and BNP against Hypoxia/Reoxygenation in Rat Engineered Heart Tissue., PLoS One. 10 (2015) e0132186. doi:10.1371/journal.pone.0132186.

L. Conradi, S. Schmidt, E. Neofytou, T. Deuse, L. Peters, A. Eder, X. Hua, A. Hansen, R.C. Robbins, R.E. Beygui, H. Reichenspurner, T. Eschenhagen, S. Schrepfer, Immunobiology of fibrin-based engineered heart tissue., Stem Cells Transl. Med. 4 (2015) 625–31. doi:10.5966/sctm.2013-0202.

M.N. Hirt, T. Werner, D. Indenbirken, M. Alawi, P. Demin, A. Kunze, J. Stenzig, J. Starbatty, A. Hansen, J. Fiedler, T. Thum, T. Eschenhagen, Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology, J. Mol. Cell. Cardiol. 81 (2015) 1–9. doi:10.1016/j.yjmcc.2015.01.008.

J. Fiedler, A. Stöhr, S.K. Gupta, D. Hartmann, A. Holzmann, A. Just, A. Hansen, D. Hilfiker-Kleiner, T. Eschenhagen, T. Thum, Functional microRNA library screening identifies the hypoxamir miR-24 as a potent regulator of smooth muscle cell proliferation and vascularization., Antioxid. Redox Signal. 21 (2014) 1167–76. doi:10.1089/ars.2013.5418.

M.N. Hirt, J. Boeddinghaus, A. Mitchell, S. Schaaf, C. Börnchen, C. Müller, H. Schulz, N. Hubner, J. Stenzig, A. Stoehr, C. Neuber, A. Eder, P.K. Luther, A. Hansen, T. Eschenhagen, Functional improvement and maturation of rat and human engineered heart tissue by chronic electrical stimulation., J. Mol. Cell. Cardiol. 74C (2014) 151–161. doi:10.1016/j.yjmcc.2014.05.009.

A. Stoehr, C. Neuber, C. Baldauf, I. Vollert, F.W. Friedrich, F. Flenner, L. Carrier, A. Eder, S. Schaaf, M.N. Hirt, B. Aksehirlioglu, C.W. Tong, A. Moretti, T. Eschenhagen, A. Hansen, Automated analysis of contractile force and Ca2+ transients in engineered heart tissue., Am. J. Physiol. Heart Circ. Physiol. 306 (2014) H1353-63. doi:10.1152/ajpheart.00705.2013.

I. Vollert, M. Seiffert, J. Bachmair, M. Sander, A. Eder, L. Conradi, A. Vogelsang, T. Schulze, J. Uebeler, W. Holnthoner, H. Redl, H. Reichenspurner, A. Hansen, T. Eschenhagen, In vitro perfusion of engineered heart tissue through endothelialized channels., Tissue Eng. Part A. 20 (2014) 854–63. doi:10.1089/ten.TEA.2013.0214.

M.N. Hirt, A. Hansen, T. Eschenhagen, Cardiac tissue engineering - state of the art, Circ. Res. 114 (2013) 354–67. doi:10.1161/CIRCRESAHA.114.300522.

A. Eder, A. Hansen, J. Uebeler, T. Schulze, C. Neuber, S. Schaaf, L. Yuan, T. Christ, M. a. Vos, T. Eschenhagen, Effects of proarrhythmic drugs on relaxation time and beating pattern in rat engineered heart tissue, Basic Res. Cardiol. 109 (2014) 436. doi:10.1007/s00395-014-0436-7.

S. Schaaf, A. Eder, I. Vollert, A. Stöhr, A. Hansen, T. Eschenhagen, A. St??hr, A. Hansen, T. Eschenhagen, Generation of Strip-Format Fibrin-Based Engineered Heart Tissue (EHT)., in: M. Radisic, L.D. Black III (Eds.), Methods Mol. Biol., Humana Press, 2014: pp. 121–9. doi:10.1007/978-1-4939-1047-2_11.

A. Stöhr, F.W. Friedrich, F. Flenner, B. Geertz, A. Eder, S. Schaaf, M.N. Hirt, J. Uebeler, S. Schlossarek, L. Carrier, A. Hansen, T. Eschenhagen, Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice., J. Mol. Cell. Cardiol. 63 (2013) 189–98. doi:10.1016/j.yjmcc.2013.07.011.

C. Crocini, T. Arimura, S. Reischmann, A. Eder, I. Braren, A. Hansen, T. Eschenhagen, A. Kimura, L. Carrier, Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue., Basic Res. Cardiol. 108 (2013) 349. doi:10.1007/s00395-013-0349-x.

M.N. Hirt, N.A. Sörensen, L.M. Bartholdt, J. Boeddinghaus, S. Schaaf, A. Eder, I. Vollert, A. Stöhr, T. Schulze, A. Witten, M. Stoll, A. Hansen, T. Eschenhagen, Increased afterload induces pathological cardiac hypertrophy: a new in vitro model., Basic Res. Cardiol. 107 (2012) 307–323. doi:10.1007/s00395-012-0307-z.

T. Eschenhagen, A. Eder, I. Vollert, A. Hansen, Physiological aspects of cardiac tissue engineering., Am. J. Physiol. Heart Circ. Physiol. 303 (2012) H133-43. doi:10.1152/ajpheart.00007.2012.

F.W. Friedrich, B.R. Wilding, S. Reischmann, C. Crocini, P. Lang, P. Charron, O.J. Müller, M.J. McGrath, I. Vollert, A. Hansen, W.A. Linke, C. Hengstenberg, G. Bonne, S. Morner, T. Wichter, H. Madeira, E. Arbustini, T. Eschenhagen, C.A. Mitchell, R. Isnard, L. Carrier, Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy., Hum. Mol. Genet. 21 (2012) 3237–54. doi:10.1093/hmg/dds157.

S. Chiron, C. Tomczak, A. Duperray, J. Lainé, G. Bonne, A. Eder, A. Hansen, T. Eschenhagen, C. Verdier, C. Coirault, Complex interactions between human myoblasts and the surrounding 3D fibrin-based matrix., PLoS One. 7 (2012) e36173. doi:10.1371/journal.pone.0036173.

L. Conradi, C. Pahrmann, S. Schmidt, T. Deuse, A. Hansen, A. Eder, H. Reichenspurner, R.C. Robbins, T. Eschenhagen, S. Schrepfer, Bioluminescence imaging for assessment of immune responses following implantation of engineered heart tissue (EHT)., J. Vis. Exp. (2011). doi:10.3791/2605.

S. Schaaf, A. Shibamiya, M. Mewe, A. Eder, A. Stöhr, M.N. Hirt, T. Rau, W.-H. Zimmermann, L. Conradi, T. Eschenhagen, A. Hansen, Human Engineered Heart Tissue as a Versatile Tool in Basic Research and Preclinical Toxicology, PLoS One. 6 (2011) e26397. doi:10.1371/journal.pone.0026397.

A. Hansen, A. Eder, M. Bönstrup, M. Flato, M. Mewe, S. Schaaf, B. Aksehirlioglu, A.P. Schwoerer, J. Uebeler, T. Eschenhagen, A. Schwörer, J. Uebeler, T. Eschenhagen, A.P. Schwoerer, Development of a drug screening platform based on engineered heart tissue., Circ. Res. 107 (2010) 35–44. doi:10.1161/CIRCRESAHA.109.211458.